These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12151466)

  • 41. Pharmacological treatment options for autism spectrum disorders in children and adolescents.
    Leskovec TJ; Rowles BM; Findling RL
    Harv Rev Psychiatry; 2008; 16(2):97-112. PubMed ID: 18415882
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.
    Chez MG; Aimonovitch M; Buchanan T; Mrazek S; Tremb RJ
    J Child Neurol; 2004 Mar; 19(3):165-9. PubMed ID: 15119476
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Case study: anorexia nervosa and autistic disorder in an adolescent girl.
    Fisman S; Steele M; Short J; Byrne T; Lavallee C
    J Am Acad Child Adolesc Psychiatry; 1996 Jul; 35(7):937-40. PubMed ID: 8768355
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antipsychotic medications in children and adolescents.
    Findling RL; Grcevich SJ; Lopez I; Schulz SC
    J Clin Psychiatry; 1996; 57 Suppl 9():19-23. PubMed ID: 8823346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risperidone use in the treatment of behavioral symptoms in children with autism.
    West L; Waldrop J
    Pediatr Nurs; 2006; 32(6):545-9. PubMed ID: 17256292
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risperidone in the treatment of two very young children with autism.
    Posey DJ; Walsh KH; Wilson GA; McDougle CJ
    J Child Adolesc Psychopharmacol; 1999; 9(4):273-6. PubMed ID: 10630457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risperidone-induced paroxysmal perceptual alteration in a child with autism.
    Bozkurt H; Ayaydın H; Adak İ; Zoroğlu SS
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):470-1. PubMed ID: 23234592
    [No Abstract]   [Full Text] [Related]  

  • 48. Risperidone in the treatment of pervasive developmental disorder.
    Purdon SE; Lit W; Labelle A; Jones BD
    Can J Psychiatry; 1994 Sep; 39(7):400-5. PubMed ID: 7527293
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Psychopharmacology in childhood disorders.
    Wiener JM
    Psychiatr Clin North Am; 1984 Dec; 7(4):831-43. PubMed ID: 6151651
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review.
    Frazier JA; Meyer MC; Biederman J; Wozniak J; Wilens TE; Spencer TJ; Kim GS; Shapiro S
    J Am Acad Child Adolesc Psychiatry; 1999 Aug; 38(8):960-5. PubMed ID: 10434487
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.
    McDougle CJ; Holmes JP; Bronson MR; Anderson GM; Volkmar FR; Price LH; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1997 May; 36(5):685-93. PubMed ID: 9136504
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clonidine: diverse use in pharmacologic management.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2011 Apr; 47(2):105-8. PubMed ID: 21426356
    [No Abstract]   [Full Text] [Related]  

  • 53. Risperidone for the core symptom domains of autism.
    Adetunji B; Mathews M; Osinowo T; Williams A
    Am J Psychiatry; 2006 Mar; 163(3):551; author reply 551-2. PubMed ID: 16513891
    [No Abstract]   [Full Text] [Related]  

  • 54. Lessons from secretin.
    Volkmar FR
    N Engl J Med; 1999 Dec; 341(24):1842-4. PubMed ID: 10588973
    [No Abstract]   [Full Text] [Related]  

  • 55. Autism spectrum disorders: update of evaluation and treatment.
    Mikhail AG; King BH
    Curr Psychiatry Rep; 2001 Oct; 3(5):361-5. PubMed ID: 11559471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacotherapy of children and adolescents with pervasive developmental disorders.
    Hanft A; Hendren RL
    Essent Psychopharmacol; 2004; 6(1):12-24. PubMed ID: 15612651
    [No Abstract]   [Full Text] [Related]  

  • 57. Brief report: autistic behaviors among children with fragile X or Rett syndrome: implications for the classification of pervasive developmental disorder.
    Mazzocco MM; Pulsifer M; Fiumara A; Cocuzza M; Nigro F; Incorpora G; Barone R
    J Autism Dev Disord; 1998 Aug; 28(4):321-8. PubMed ID: 9711488
    [No Abstract]   [Full Text] [Related]  

  • 58. [Useful pharmacologic treatment in impaired social interaction in autism spectrum disorders].
    Yui K
    Seishin Shinkeigaku Zasshi; 2012; 114(8):934-40. PubMed ID: 23012855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The challenges of psychopharmacological management of children with severe developmental disabilities.
    Ivanov I; Klein M; Green WH; Coffey B
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):793-9. PubMed ID: 17201623
    [No Abstract]   [Full Text] [Related]  

  • 60. From the Editor-in-Chief's Desk.
    Koplewicz HS
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):457. PubMed ID: 26262901
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.